Nagase & Co., Ltd. Overview
Nagase & Co. is Japan's oldest and largest independent specialty-chemicals trading house. Founded in Kyoto in 1832, it is preparing for its bicentennial in 2032. Over the past two decades it has turned from a pure distributor into a hybrid "trading × manufacturing × R&D" group. The trading core sells resins, specialty chemicals, electronic and battery materials, automotive materials, food ingredients and pharmaceutical intermediates across about 30 countries. Captive manufacturers sit behind it:
-
Nagase ChemteX: formulated epoxy resins and liquid encapsulants for AI semiconductors
-
Nagase Viita (ex-Hayashibara): trehalose, pullulan and enzymes
-
Prinova Group (US): food and nutrition ingredients, premixes and contract manufacturing
-
Pac Tech (Germany): wafer bumping
-
Recently acquired Nagase Circrea (ex-SACHEM Asia): high-purity chemicals and TMAH developer recycling
-
Recently acquired Nagase Diagnostics (ex-Asahi Kasei Pharma diagnostics)
FY2026 net sales were ¥972.8 billion and operating income ¥44.7 billion, both records, with ROE of 8.0%. The investment case rests on mix-shift toward higher-margin proprietary materials, ROIC discipline and a 100% total-payout capital policy.
Company's own description
In the Yuho and integrated report, Nagase describes itself as a materials company that "solves manufacturing challenges through materials." It combines three functions:
Trading: information "discernment" (目利き), problem discovery and matching, and a global network
Manufacturing: proprietary materials and technology, quality control, customisation
R&D: new-material and application development
The internal maxim is "When in trouble, ask NAGASE" (「困ったらNAGASEに聞け!」). The Yuho states that the group's main activities are import, export and domestic trading of goods, plus manufacture and sale of products and provision of services across a wide range of industrial sectors.
For FY2026 the group reported through five segments: Functional Materials, Advanced Materials & Processing, Electronics & Energy, Mobility, and Life & Healthcare. From FY2027 (April 2026) these were consolidated into three segments:
Materials: Functional Materials + Advanced Materials & Processing + Mobility
Electronics: former Electronics & Energy
Life Sciences: former Life & Healthcare
(FY2027 Q1 Financial Briefing, 4 Aug 2026.)
Business model and revenue model
| Metric | Trading | Manufacturing |
|---|---|---|
| Gross profit (JPY 100M) | 1,324 | 552 |
| Operating income (JPY 100M) | 333 | 113 |
| Share of operating income | ~75% | ~25% |
Nagase earns revenue in two ways that it now discloses separately.
(a) Trading business. Nagase and its sales subsidiaries buy and resell chemicals, resins, materials and ingredients. Margin comes from the spread plus technical-service and supply-chain value. Trading gross margins are typically mid-teens percent. Trading also books the sales of certain captive manufacturers' products, because Nagase handles their sales function.
(b) Manufacturing business. The aggregate of manufacturing subsidiaries, including Nagase ChemteX Group, Nagase Viita, Prinova's manufacturing arm, Pac Tech and Nagase RooTAC. Gross margins run ~35–40% at Nagase ChemteX and Nagase Viita.
In FY2026 (restated, company basis):
(FY2027 Q1 Briefing, quarterly appendix.)
The revenue model is overwhelmingly product sales, both distribution and manufactured goods. Service revenue includes:
-
contract bumping services (Pac Tech)
-
contract manufacturing and premix "Solutions" (Prinova)
-
LCD glass-thinning processing (Nagase Electronic Technology Xiamen)
-
radiation-dosimetry services (Nagase-Landauer, equity method)
-
TMAH developer collection and recycling (Nagase Circrea)
There is no material subscription or licensing revenue; a split by revenue type is not publicly disclosed.
Value-chain position
Nagase sits mid-stream. It sources from global chemical majors (historically Ciba-Geigy, Union Carbide, Eastman Kodak, GE) and from its own plants. It sells to converters, compounders and OEMs in electronics/semiconductors, automotive, coatings and inks, plastics processing, food and beverages, cosmetics, and pharmaceuticals and diagnostics. Its differentiation is formulation know-how, application development (Nagase Application Workshop, Amagasaki) and supply-chain resilience. The last point was shown in Q1 FY2027, when Nagase sourced substitute petrochemicals during the Strait of Hormuz-related naphtha shortage (FY2027 Q1 Briefing).
Customer types and end-markets (FY2026 segment basis)
| End-market | Primary segment(s) | FY2026 demand commentary (company) |
|---|---|---|
| Electrical & electronic equipment | Advanced Materials & Processing / Materials | Demand and resin market conditions grew slightly YoY |
| Automobiles | Mobility / Materials | EV demand declined; slight overall decrease YoY |
| Coatings | Functional Materials / Materials | Automotive and construction applications decreased slightly |
| Semiconductors | Electronics & Energy / Electronics | AI-driven growth; China domestic production expanding; overall favourable |
| Smartphones | Electronics | Overall market flat YoY due to slowdown in China |
| Food | Life & Healthcare / Life Sciences | Strong in Japan; favourable in Europe and US |
| Cosmetics | Life Sciences | Structural change from weak China demand |
| Medical / pharma | Life Sciences | Additive, API and intermediate demand strong |
(FY2027 Q1 Briefing, "Business Environment Surrounding NAGASE Segments".)
Independent characterisation
Nagase is best read as a specialty distributor with an embedded portfolio of niche manufacturers. It is not a sogo shosha. Its consolidated operating margin (4.6% in FY2026) is structurally capped by the trading mix. Value creation depends on three things:
-
the faster-growing, higher-margin manufacturing assets: Nagase ChemteX (operating margin 11.5% in FY2026, 17.1% in Q1 FY2027) and Nagase Viita (16.5% before goodwill amortisation)
-
returning Prinova (operating margin 3.3%; ¥214.2bn sales in FY2026) to its acquisition-case returns
-
disciplined capital allocation, now explicitly ROIC-driven
The business is cyclical in its trading spreads (resin and chemical market prices) but diversified across end-markets. The Life Sciences leg (~32% of sales) gives some defensiveness.
Strategy
Long-term vision
The vision is "Ideal NAGASE 2032": a "Business Designer that Creates a Sustainable Future", timed to the 200th anniversary. The management philosophy is "walking the right path with sincerity"; the stated vision is creating a safe, secure and warm society in which people can live comfortably (CEO message, Apr 2023).
ACE 2.0 (FY2022–FY2026) — outcome
| ACE 2.0 KGI | Target | FY2026 actual | Result |
|---|---|---|---|
| ROE | ≥8.0% | 8.0% | Achieved |
| Operating income | ¥35.0bn | ¥44.7bn | Exceeded |
| Total payout ratio (time-limited) | 100% | 100.7% (FY2026); 105.4% (FY2025) | Achieved |
| Cross-shareholding reduction | ~¥30bn over 5 years | Ongoing; gains on sale ¥2.8bn (FY2025), ¥3.5bn (FY2026) | Progressing |
| Scope 1+2 GHG reduction vs FY2013 | ≥37% (2022 KPI); later 46% by 2030 | 43% achieved (FY2025, Integrated Report 2025) | Ahead of interim KPI |
| Engagement survey score | ≥67 total score (revised KPI) | — | — |
The plan's theme was "Pursuit of Quality" under three pillars: Accountability, Commitment, Efficiency. Businesses were classified into four quadrants:
Foundation: (基盤)
Focus: (注力): proprietary products and technologies to lift profitability
Development: (育成): bio R&D, semiconductors, food, life sciences, new products, Global South; potential investment ≈ ¥80bn from FY2024 (Kitaishihon summary)
Improvement: (改善): fix or exit
(Integrated Report 2025 via Kitaishihon; Envalith; company KPI notice, May 2022.)
"Walk the Talk 2028" (FY2027–FY2029), announced 7 May 2026
| Element | Detail |
|---|---|
| Profit target | Operating income above ¥50.0bn by the final year (FY2029, company "fiscal 2028") |
| Return target | ROE ≥9.0% |
| EPS | Guideline of +30% EPS growth over three years (≈9% CAGR from ¥78.89) |
| Market value | Aspiration of a ¥1 trillion market capitalisation (FilingReader summary; timeframe not specified in sources) |
| Growth investment | ¥100bn, focused on expanding semiconductor materials and improving nutrition-business efficiency (Prinova) |
| Shareholder returns | 100% total payout ratio; progressive "stable dividend increases" over three years; flexible buybacks |
| Funding | Sale of policy (cross-) shareholdings |
| Structure | Five segments consolidated into three (Materials, Electronics, Life Sciences) from April 2026 |
Initiatives in the last 24 months
| Initiative | Date | Description | Status |
|---|---|---|---|
| Nagase Diagnostics | Announced Sep 2024; live 1 Jul 2025 | Acquired Asahi Kasei Pharma's diagnostics business and Ohito plant; Focus (life-science manufacturing) and Development (biotech) | Consolidated FY2026 |
| SACHEM Asia / Nagase Circrea | Announced Mar 2025; closed 2 Jun 2025 | High-purity chemicals and TMAH developer recycling (circular economy × semiconductors) | Integrated and renamed Mar–Apr 2026 |
| Prinova — Aplinova | Apr 2025 | Brazil ingredients distribution; Global South push | Consolidated (Apliquimica) |
| Nagase Wahlee India | Announced May 2025; ops Jun 2025 | Resin sales JV (NWP Taiwan × Nagase India), targeting China/Taiwan supply-chain relocation to India | Consolidated |
| Nagase India Pune branch | 1 Dec 2025 | Automotive and chemical cluster coverage | Operating |
| India semiconductor logistics with Nippon Express | Jan 2026 | High-tech supply chain for front-end semiconductor materials in Dholera, Gujarat (GlobalData) | Announced |
| California biotech lab | Jan 2026 | Robotics- and AI-driven new-material discovery | Opened |
| Nagase ChemteX capacity | FY2026 | Capacity expansion for modified epoxy resins and liquid encapsulants for AI semiconductors; a-SMC development (Envalith summary) | Small-volume a-SMC production (Q1 FY2027) |
| Dodai Group stake | Apr 2026 | Partial share acquisition (GlobalData). Dodai is understood to be an e-mobility start-up | Unconfirmed details |
| Prinova Nutrition efficiency programme | FY2025–FY2027 | Loss reduction in Nutrition; separate manufacturing/trading disclosure from FY2027 | Loss narrowing |
| Materiality revision | Sep 2024 | Added healthy-lifespan extension, supply-chain sustainability and circular economy to engagement, decarbonisation and governance | Adopted |
| Capital policy | FY2025–FY2027 | 4:1 split (Apr 2026); buybacks ¥17.0bn (FY2025), ¥23.0bn (FY2026), ¥3.0bn (Aug–Sep 2026) | Ongoing |
Management guidance (FY2027, unchanged at Q1, 4 Aug 2026)
| Guidance item (JPY 100M) | FY2026 actual | FY2027 guidance |
|---|---|---|
| Net sales | 9,727 | 10,000 |
| Gross profit | 1,876 | 1,980 |
| SG&A | 1,429 | 1,530 |
| Operating income | 447 | 450 |
| Operating income excl. actuarial effect | 450 | 409 |
| Ordinary income | 440 | 450 |
| Profit attributable to owners | 331 | 345 |
| EPS (JPY) | 78.89 | 84.59 |
| DPS (JPY) | 25.00 | 27.00 |
Assumptions:
-
USD/JPY 155.0; RMB/JPY 22.5
-
Sensitivity of operating income to a ¥1 depreciation: USD +¥50m, RMB +¥400m
Q1 FY2027 progress: the first quarter achieved 38% of full-year operating income guidance (¥17.0bn) and 42% of net income guidance. Management will reassess the forecast at the H1 results in early November 2026 because of Middle East uncertainty.
Products & Services
Pricing models are not publicly disclosed for any product line. Nagase sells B2B on negotiated, mostly spot or contract pricing. "Launch year" is given where disclosed.
Functional Materials → Materials (from FY2027)
| Product line | Description / capabilities | Target customer | Notes / flagship |
|---|---|---|---|
| Coating & ink raw materials | Resins, pigments, dispersions, additives for automotive, construction and industrial coatings and printing inks | Paint and ink makers | FY2026 sales declined on weak automotive and construction demand (Envalith summary of Yuho) |
| Urethane raw materials & auxiliaries | Polyols/isocyanate-related materials, release agents | Urethane foam converters (construction, automotive, industrial) | Equity affiliate Cytech Products (Kentucky, 35%) makes urethane release agents |
| Semiconductor material raw materials / electronics chemicals | High-purity chemicals, electronics chemicals, fluorine chemicals | Semiconductor and electronic-material makers | FY2026 growth area within the segment |
| Specialty epoxy, solvents, silicones | Upstream intermediates | Formulators | Long-standing agency relationships |
| Functional films/sheets, adhesives, sanitary materials | Converted and functional films; nonwoven/sanitary inputs | Hygiene, packaging, industrial | — |
| Water treatment & environmental products | Water-treatment equipment, metal-organic frameworks (MOFs), CO2-capture equipment | Industrial, environmental | Development-stage new business |
Advanced Materials & Processing → Materials
| Product line | Description | Target customer | Notes |
|---|---|---|---|
| Engineering & commodity plastics | Distribution and compounding of thermoplastics (PC, PA, PBT, ABS etc.) | E&E equipment, OA, appliances, automotive tier suppliers | Taiwan JV Nagase Wahlee Plastics is a major Asian resin distributor; Nagase Wahlee India started June 2025 |
| Thermosetting resins & synthetic-resin products | Resin products and compounds | Converters | Nagase Plastics Co. (Osaka) |
| Molding machines & molds | Equipment trading; equity affiliate Automotive Mold Technology (Rayong, 32.1%) | Molders | — |
| Packaging materials | Films and packaging; Nafuko (Bangkok, 28%) packaging affiliate | FMCG, food | — |
| Industrial hoses & civil-engineering pipes | Manufactured by Nagase RooTAC Industries | Industrial and civil engineering | Sales rose in Q1 FY2027 |
| Digital-print processing materials | Manufacturing business | Printing | Noted as weak in earlier periods (FY2023 briefing) |
| Colour masterbatch | Dainichi Color Vietnam (40%, equity method) | Plastics processors | — |
Electronics & Energy → Electronics
| Product line | Description / key capabilities | Target customer | Notes / flagship |
|---|---|---|---|
| Formulated (modified) epoxy resins — Nagase ChemteX | Epoxy formulations incl. LMC (Liquid Molding Compound) for advanced semiconductor packaging | OSATs, IDMs, AI-semiconductor supply chain | LMC sales for AI semiconductors rose while mobile-device sales fell (Q1 FY2027) |
| a-SMC (Advanced Sheet Molding Compound) | Encapsulant for high-performance IC package substrates | Advanced-package substrate makers | Adopted; small-volume production started (Q1 FY2027 Briefing) |
| Photolithography materials | Developers, strippers and process chemicals | Display and semiconductor fabs | Sales flat; cost efficiencies lifted profit (Q1 FY2027) |
| Epichlorohydrin derivatives, conductive materials, functional dyes | Nagase ChemteX specialty chemistries (incl. Denacol-type epoxy compounds; brand per analyst knowledge) | Industrial and electronics | — |
| High-purity chemicals & catalysts — Nagase Circrea (ex-SACHEM Asia) | High-purity chemicals for semiconductors, catalysts, specialty chemicals; Wuxi manufacturing | Semiconductor and FPD fabs (China, Korea, Japan, Taiwan) | Acquired June 2025 |
| TMAH developer recovery & regeneration | Collection and recycling of used TMAH developer | TFT/FPD and semiconductor fabs | Described as Japan's first TMAH recovery/regeneration business (Envalith summary of company IR); legacy SN Tech JV with SACHEM, ~15 years |
| Wafer bumping equipment & contract bumping — Pac Tech | Laser-based solder-ball and electroless plating bumping | Semiconductor packaging | Strong bumping contract services (Q1 FY2027) |
| LCD glass thinning | Chemical etching of glass panel units (Nagase Electronic Technology, Xiamen) | Display makers | — |
| Display optical materials, touch-panel parts, abrasives, 3D-printing materials | Trading | Display and electronics OEMs | Nagase Abrasive Materials deconsolidated in FY2026 (reason not disclosed) |
| Siloxane functional materials (Inkron) | Functional materials for semiconductors and devices | Device makers | Inkron Oy deconsolidated in FY2026; Inkron Limited (HK) remains a specified subsidiary |
| Precision plastic lenses & optical units | Nissei Technology (20%, equity method) | Optics | — |
| Nagase ChemteX Group (JPY 100M) | FY2026 | FY2027F |
|---|---|---|
| Sales | 330 | 356 |
| Gross profit | 117 | 125 |
| Operating income | 37 | 37 |
Nagase ChemteX Group financials (JPY 100M; restated to include Wuxi and America units):
Q1 FY2027 operating income was ¥1.7bn (17.1% margin) versus ¥0.9bn a year earlier.
Mobility → Materials
| Product line | Description | Target customer | Notes |
|---|---|---|---|
| Automotive resins & functional materials | Resins, functional paints, adhesives for interiors/exteriors and functional parts | Japanese and global OEMs, tier-1s | Solid in Q1 FY2027, partly on new adoptions |
| Battery & electrification materials | Secondary-battery materials, electrification components | EV/battery supply chain | Weak EV demand cited in FY2026 |
| HMI / in-vehicle electronics components | Human-machine interface components, ADAS-related materials | Tier-1s | — |
| Seat-pad urethane | TQ-1 de Mexico (25%) | Automotive seating | Equity method |
| Automotive parts (India) | Uno Minda Kyoraku (20%, Haryana) | Indian OEMs | Equity method |
Life & Healthcare → Life Sciences
| Product line | Description / capabilities | Target customer | Notes / flagship |
|---|---|---|---|
| Prinova Group — ingredients distribution | Vitamins, amino acids, sweeteners, flavours, aroma chemicals, citrus oils etc. | Food, beverage, nutrition, flavour houses | Trading GP ¥23.9bn in FY2026; profit pressured by logistics costs in Q1 FY2027 |
| Prinova — Solutions (premix and contract manufacturing) | Custom nutrient premixes, powder blending, finished-product contract manufacturing | Nutrition and CPG brands | Main driver of manufacturing recovery in FY2026–FY2027 |
| Prinova — Nutrition business | Nutrition manufacturing | Nutrition brands | Loss narrowing on sales growth and efficiency (Q1 FY2027) |
| Prinova Latin America | Aplinova (Brazil ingredients distribution, acquired Apr 2025); Flavor Tec (Brazil citrus-oil processor, acquired 2023) | LATAM food and beverage | Fruttini Sucos de Frutas Ltda deconsolidated in FY2026 |
| Prinova Asia | Prinova Solutions Asia (HK), Prinova nutrition technology (Changzhou) | Asian food/nutrition | — |
| Nagase Viita (ex-Hayashibara) — food ingredients | Trehalose (TREHA brand), pullulan, functional saccharides, phospholipids | Food processors | Raw-material inflation hit food margins in Q1 FY2027 |
| Nagase Viita — cosmetics ingredients | Functional actives incl. ascorbic-acid derivatives (e.g. AA2G; brand per analyst knowledge) | Cosmetics makers (Japan and overseas) | Volume up in Q1 FY2027 |
| Nagase Viita — pharma additives & enzymes | Pharmaceutical excipients, industrial enzymes | Pharma, industry | — |
| Bio-derived super-absorbent polymer (SAP) | Biodegradable SAP for adult diapers, greening and agricultural water retention | Hygiene, agriculture | Highlighted in Integrated Report 2025 |
| Pharmaceutical intermediates & APIs | Trading of intermediates and APIs | Pharma (branded and generic) | FY2027 Q1 sales flat |
| Nagase Diagnostics | Diagnostic reagents, diagnostic enzymes, life-science raw materials | IVD makers | Ex-Asahi Kasei Pharma diagnostics business plus Ohito plant; consolidated 1 Jul 2025; 205 employees at formation |
| Cosmetics/beauty care | Nagase Beauty Care Co. | Consumers / brands | Scale not disclosed |
| Radiation dosimetry service | Nagase-Landauer (50%, equity method) | Hospitals, nuclear, industry | — |
| Major manufacturing subsidiaries (JPY 100M) | FY2026 | FY2027F |
|---|---|---|
| Nagase Viita sales | 346 | 350 |
| Nagase Viita operating income before goodwill/intangible amortisation | 57 | 51 |
| Nagase Viita operating income after amortisation | 38 | 32 |
| Prinova Group sales | 2,142 | 2,420 |
| Prinova Group operating income before amortisation | 69 | 80 |
| Prinova Group operating income after amortisation | 42 | 51 |
Nagase Viita and Prinova Group (JPY 100M):
(FY2027 Q1 Briefing.)
Corporate / others
| Line | Description |
|---|---|
| IT and functional services | Information processing and functional services (Nagase Business Expert etc.) |
| Logistics | Senko Nagase Logistics (15%, equity method; warehousing and transport, Amagasaki) |
| Dye trading | OG Nagase Color Chemical (50%, equity method) |
| Biotech R&D platform | Nagase Bio Innovation Center (Kobe); new California biotechnology lab using robotics and AI, opened Jan 2026 (Envalith summary of company IR) |
Financial Narrative
Sources: Kessan Tanshin FY2026 (7 May 2026) for FY2025–FY2026. S&P Global Market Intelligence via StockAnalysis (data updated 30 Jun 2026) for FY2022–FY2024 and balance-sheet/cash-flow line items.
Comparability warnings:
Revenue recognition: FY2022 is the first year under Japan's new revenue-recognition standard (ASBJ No. 29). Its revenue is not comparable with FY2021 (¥830bn reported on the old gross basis).
Gross profit: FY2025 gross profit was restated retrospectively for an accounting-policy change, from ¥181,291m originally to ¥173,301m. Roughly ¥8.0bn of costs moved from SG&A into cost of sales; operating income was unchanged. FY2022–FY2024 gross profit is on the pre-change basis, so the reported gross margin uplift from FY2024 to FY2026 is understated, not overstated.
Income statement
Notes:
Diluted EPS: not presented by the company; no dilutive securities.
Ordinary income: ¥38,382m (FY2025) and ¥44,096m (FY2026), Kessan Tanshin.
EBITDA definition: analyst-defined. Matsui Securities shows FY2026 EBITDA of ¥61,636m on a different definition. This discrepancy is noted.
EPS sources: FY2022–FY2024 post-split EPS from ROIC.ai (S&P data), consistent with net income divided by about 4 × the pre-split average share count.
Margins
Growth rates FY2022→FY2026 (analyst calculation):
-
Revenue CAGR: 5.7% (¥780.6bn → ¥972.8bn)
-
Operating income CAGR: 6.1%
-
Net income CAGR: 6.3%
-
EPS CAGR: 10.3%, boosted by buybacks
Commentary. Three phases are visible.
FY2022–FY2024: margin compression: Operating income fell from ¥35.3bn to ¥30.6bn. Inflationary resin and chemical pricing in FY2022–FY2023 initially lifted sales (+17% in FY2023) but compressed margins. SG&A grew faster than gross profit (+29% vs +18% over two years) as Prinova's cost base expanded and wage and logistics costs rose. Inventory destocking hit electronics and automotive chemicals in FY2024.
FY2025: inflection: Operating income rose 27.6% to ¥39.1bn. Drivers were Electronics & Energy (+39% OI on semiconductor materials), Functional Materials (+50%) and ~¥3.5bn of actuarial gains in retirement-benefit expense. Life & Healthcare collapsed to ¥3.4bn on Prinova problems, including a ~¥1.3bn bad-debt provision in FY2025 Q2.
FY2026: record: Operating income reached ¥44.7bn (+14.5%) despite the actuarial swing turning to a ~¥0.3bn loss. Gross profit rose 8.3% on 2.9% sales growth (margin +1.0pt), the clearest evidence that the ROIC-driven mix strategy is working. Electronics & Energy (+20.8% OI, Nagase ChemteX AI-semiconductor epoxy) and the Life & Healthcare recovery (+187% OI as Prinova manufacturing turned around and Nagase Viita intangible amortisation partly ended) were the drivers. Net income rose 29.8% to ¥33.1bn, helped by:
-
¥3.5bn gain on sale of investment securities (cross-shareholding unwinding)
-
¥1.78bn gain on bargain purchase (attributable to the SACHEM Asia acquisition; analyst inference, as the company does not name the transaction)
-
a lower tax rate
Balance sheet
Company-defined measures (FY2026 Q1 FY2027 Briefing):
-
Interest-bearing debt: ¥191.0bn at 31 Mar 2026; ¥216.3bn at 30 Jun 2026
-
Net D/E ratio: 0.34 (Mar 2026); 0.39 (Jun 2026)
-
Shareholders' equity ratio: 48.8% (Mar 2026); 47.4% (Jun 2026)
FY2026 debt composition (Kessan Tanshin):
-
Short-term loans ¥20.2bn (down from ¥42.3bn)
-
Commercial paper ¥47.0bn (up from ¥19.5bn)
-
Current portion of long-term loans ¥15.0bn
-
Bonds ¥40.0bn
-
Long-term loans ¥50.0bn
-
Lease liabilities ¥16.1bn
Commentary. The balance sheet is conservative for a trading house: equity ratio ~49%, net D/E ~0.3x. Three FY2026 moves stand out:
-
Cash fell ¥20.5bn and net debt rose ¥36bn. The causes were acquisitions (¥19.1bn of subsidiary-share purchases), doubled capex (¥25.4bn) and ¥23.0bn of buybacks.
-
PP&E jumped from ¥91.7bn to ¥124.0bn on newly consolidated SACHEM Asia and Nagase Diagnostics assets and capacity additions.
-
Accumulated other comprehensive income rose ¥24.2bn (securities valuation +¥9.8bn, translation +¥11.3bn). Equity is therefore sensitive to the yen and to the cross-shareholding portfolio (investment securities ¥87.6bn).
Cash flow
Commentary. Nagase's cash flow is dominated by working capital, which is typical of distribution:
-
FY2022–FY2023: inflation absorbed ¥84bn of working capital and drove negative free cash flow.
-
FY2024: destocking released ¥35bn and produced a ¥58.9bn free-cash-flow peak.
-
FY2025–FY2026: normalised free cash flow of ~¥22–24bn per year.
Shareholder returns in those two years (¥26.6bn and ¥32.6bn) exceeded free cash flow, funded by asset sales (cross-shareholdings) and incremental debt. This is consistent with ACE 2.0's time-limited 100% total-payout policy.
Q1 FY2027 operating cash flow was −¥21.2bn, after a ¥30.6bn working-capital build on Middle East-driven price spikes and precautionary customer buying. That is a reminder of cash volatility.
Ratios
Notes:
-
Company-reported ROE: 6.4% (FY2025), 8.0% (FY2026).
-
The company's own ROIC definition differs. Its FY2026 forecast ROIC was 5.2% (Integrated Report 2025 via Kitaishihon).
Commentary. ROE has finally cleared the 8% ACE 2.0 hurdle. ROIC of roughly 5% sits close to a plausible WACC of 5–6% (company WACC not disclosed in the sources reviewed), so economic value creation is marginal. The new plan's ≥9% ROE target relies heavily on EPS accretion from buybacks and cross-shareholding sales, not only on operating improvement. The cash conversion cycle of ~125–130 days is long. Each 10 days of improvement would release about ¥27bn of cash at FY2026 sales levels (analyst calculation).
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansFinancial Detail
Segment (FY2026) Overview
| Segment (FY2026) | Contents | Principal products / services |
|---|---|---|
Functional Materials (機能素材) | Upstream functional chemicals | Coating and ink raw materials, pigments, additives, urethane raw materials and auxiliaries, electronics chemicals, high-purity chemicals, surfactants, specialty epoxy, solvents, silicones, functional films/sheets, sanitary materials, water-treatment products, MOFs, CO2-capture equipment |
Advanced Materials & Processing (加工材料) | Plastics and processing | Engineering and commodity plastics, thermoplastic and thermosetting resins, synthetic-resin products, packaging materials, molding machines and molds, digital-print processing materials, industrial hoses and civil-engineering pipes (Nagase RooTAC) |
Electronics & Energy (電子・エネルギー) | Electronics and semiconductor materials | Formulated/modified epoxy resins and liquid encapsulants (Nagase ChemteX), photolithography materials, high-purity chemicals and TMAH developer recycling (Nagase Circrea), wafer bumping equipment and contract services (Pac Tech), display optical materials, touch-panel components, LCD glass thinning (Xiamen), abrasive materials, 3D-printing materials |
Mobility (モビリティ) | Automotive | Resins, functional paints, adhesives, battery and electrification materials, interior/exterior and functional-part materials, HMI components |
Life & Healthcare (生活関連) | Food, cosmetics, pharma, diagnostics | Food ingredients (Prinova; Nagase Viita trehalose, pullulan), premixes and contract manufacturing, cosmetics raw materials, pharma intermediates and APIs, pharmaceutical additives, enzymes, diagnostic reagents (Nagase Diagnostics), health foods |
Segment net sales (JPY Mn)
| Segment net sales (JPY Mn) | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Functional Materials | 99,874 | 156,161 | 146,804 | 153,746 | 153,642 |
Advanced Materials & Processing | 257,283 | 220,955 | 198,543 | 210,627 | 206,690 |
Electronics & Energy | 128,131 | 136,975 | 144,758 | 161,315 | 172,891 |
Mobility | 103,389 | 125,560 | 132,117 | 132,091 | 130,256 |
Life & Healthcare | 191,634 | 273,161 | 277,779 | 287,079 | 309,207 |
Segment operating income (JPY Mn)
| Segment operating income (JPY Mn) | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Functional Materials | 7,823 | 10,486 | 6,158 | 9,213 | 9,305 |
Advanced Materials & Processing | 10,858 | 7,678 | 5,313 | 6,684 | 7,650 |
Electronics & Energy | 10,278 | 9,273 | 8,852 | 12,302 | 14,859 |
Mobility | 4,131 | 4,794 | 3,614 | 4,238 | 3,785 |
Life & Healthcare | 9,429 | 10,581 | 8,006 | 3,423 | 9,832 |
Segment operating margin (%)
| Segment operating margin (%) | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Functional Materials | 7.8 | 6.7 | 4.2 | 6.0 | 6.1 |
Advanced Materials & Processing | 4.2 | 3.5 | 2.7 | 3.2 | 3.7 |
Electronics & Energy | 8.0 | 6.8 | 6.1 | 7.6 | 8.6 |
Mobility | 4.0 | 3.8 | 2.7 | 3.2 | 2.9 |
Life & Healthcare | 4.9 | 3.9 | 2.9 | 1.2 | 3.2 |
Segment Revenue
| Segment | Sales YoY FY2025 (%) | Sales YoY FY2026 (%) | OI YoY FY2025 (%) | OI YoY FY2026 (%) | Share of sales FY2024 (%) | Share of sales FY2025 (%) | Share of sales FY2026 (%) |
|---|---|---|---|---|---|---|---|
Functional Materials | 4.7 | -0.1 | 49.6 | 1.0 | 16.3 | 16.3 | 15.8 |
Advanced Materials & Processing | 6.1 | -1.9 | 25.8 | 14.5 | 22.1 | 22.3 | 21.2 |
Electronics & Energy | 11.4 | 7.2 | 39.0 | 20.8 | 16.1 | 17.1 | 17.8 |
Mobility | 0.0 | -1.4 | 17.3 | -10.7 | 14.7 | 14.0 | 13.4 |
Life & Healthcare | 3.3 | 7.7 | -57.2 | 187.2 | 30.9 | 30.4 | 31.8 |
Segment Overview
| Segment | Segment assets (JPY Mn) | Capex (JPY Mn) | Depreciation (JPY Mn) | Employees | Segment ROA (%) |
|---|---|---|---|---|---|
Functional Materials | 122,493 | 1,949 | 802 | 872 | 7.6 |
Advanced Materials & Processing | 116,249 | 1,366 | 886 | 1,144 | 6.6 |
Electronics & Energy | 111,954 | 4,591 | 2,805 | 1,611 | 13.3 |
Mobility | 70,069 | 171 | 257 | 301 | 5.4 |
Life & Healthcare | 284,077 | 6,471 | 7,518 | 2,657 | 3.5 |
Revenue by Segment (JPY)
| New segment (JPY 100M) | FY2026 actual sales | FY2026 actual GP | FY2026 actual OI | FY2027 forecast sales | FY2027 forecast GP | FY2027 forecast OI |
|---|---|---|---|---|---|---|
Materials | 4,905 | 757 | 214 | 4,955 | 776 | 196 |
Electronics | 1,728 | 453 | 153 | 1,750 | 479 | 144 |
Life Sciences | 3,092 | 664 | 86 | 3,294 | 724 | 72 |
Corporate & Others | 0 | 1 | -7 | 0 | 0 | 38 |
Total | 9,727 | 1,876 | 447 | 10,000 | 1,980 | 450 |
Segment Revenue (Quarterly)
| New segment | Q1 FY2026 sales | Q1 FY2027 sales | Q1 FY2026 OI | Q1 FY2027 OI | OI YoY (%) |
|---|---|---|---|---|---|
Materials | 1,189 | 1,403 | 50 | 81 | 63 |
Electronics | 415 | 491 | 30 | 49 | 60 |
Life Sciences | 768 | 902 | 21 | 29 | 37 |
Income Statement and Margin Analysis (%)
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Net sales (JPY Mn) | 780,557 | 912,896 | 900,149 | 944,961 | 972,783 |
Net sales growth YoY (%) | -6.0 | 17.0 | -1.4 | 5.0 | 2.9 |
Gross profit (JPY Mn) | 139,495 | 155,410 | 164,719 | 173,301 | 187,687 |
SG&A incl. goodwill amortisation (JPY Mn) | 104,231 | 122,038 | 134,100 | 134,222 | 142,959 |
Operating income (JPY Mn) | 35,264 | 33,372 | 30,619 | 39,078 | 44,727 |
D&A incl. goodwill amortisation (JPY Mn) | 13,694 | 14,922 | 16,625 | 18,051 | 19,599 |
EBITDA = OI + D&A (JPY Mn) | 48,958 | 48,294 | 47,244 | 57,129 | 64,326 |
Interest expense (JPY Mn) | 1,176 | 3,211 | 3,744 | 3,734 | 3,348 |
Income before income taxes (JPY Mn) | 39,557 | 33,137 | 32,665 | 38,130 | 45,977 |
Profit attributable to owners of parent (JPY Mn) | 25,939 | 23,625 | 22,402 | 25,521 | 33,119 |
EPS basic, post-split (JPY) | 53.36 | 49.88 | 48.74 | 57.60 | 78.89 |
Dividend per share, post-split (JPY) | 13.5 | 17.5 | 20.0 | 22.5 | 25.0 |
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansMargin (%)
| Margin (%) | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Gross margin | 17.9 | 17.0 | 18.3 | 18.3 | 19.3 |
Operating margin | 4.5 | 3.7 | 3.4 | 4.1 | 4.6 |
EBITDA margin | 6.3 | 5.3 | 5.2 | 6.0 | 6.6 |
Net margin | 3.3 | 2.6 | 2.5 | 2.7 | 3.4 |
Balance Sheet and Per-Share Data
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Total assets (JPY Mn) | 739,720 | 762,688 | 792,336 | 808,143 | 871,526 |
Cash & deposits (JPY Mn) | 54,211 | 40,897 | 59,410 | 66,310 | 45,599 |
Trade receivables (JPY Mn) | 288,614 | 301,084 | 320,186 | 310,203 | 320,499 |
Inventories (JPY Mn) | 157,524 | 169,720 | 147,990 | 166,222 | 177,559 |
Short-term debt incl. CP and current LTD (JPY Mn) | 116,873 | 105,173 | 104,677 | 67,849 | 82,175 |
Long-term debt incl. bonds (JPY Mn) | 48,244 | 62,697 | 47,533 | 93,454 | 90,000 |
Lease liabilities, long-term (JPY Mn) | 0 | 9,763 | 12,492 | 11,471 | 16,077 |
Total debt incl. leases (JPY Mn) | 165,117 | 177,633 | 164,702 | 172,774 | 188,252 |
Net debt (JPY Mn) | 110,906 | 136,736 | 105,292 | 106,464 | 142,653 |
Shareholders' equity (owners of parent) (JPY Mn) | 344,261 | 367,674 | 394,064 | 399,052 | 425,445 |
Total net assets (JPY Mn) | 355,091 | 378,387 | 401,314 | 406,458 | 434,023 |
Goodwill (JPY Mn) | 29,492 | 29,004 | 27,884 | 25,400 | 28,384 |
Other intangibles (JPY Mn) | 35,578 | 39,924 | 41,465 | 40,411 | 40,304 |
Working capital (JPY Mn) | 206,450 | 243,929 | 239,795 | 290,550 | 269,311 |
Book value per share, post-split (JPY) | 717.05 | 784.81 | 865.96 | 919.77 | 1,043.19 |
Cash Flow
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Operating cash flow (JPY Mn) | -17,776 | 9,414 | 72,959 | 36,321 | 47,805 |
Change in working capital (JPY Mn) | -60,577 | -23,521 | 35,391 | -5,552 | -3,379 |
Capex, PP&E (JPY Mn) | 8,830 | 12,029 | 14,019 | 12,554 | 25,351 |
Free cash flow = OCF − PP&E capex (JPY Mn) | -26,606 | -2,615 | 58,940 | 23,767 | 22,454 |
Acquisitions, net of cash (JPY Mn) | 3,848 | 0 | 244 | 0 | 19,071 |
Investing cash flow (JPY Mn) | -7,664 | -8,031 | -11,627 | -11,615 | -46,511 |
Dividends paid (JPY Mn) | 5,876 | 7,150 | 9,281 | 9,557 | 9,604 |
Share buybacks (JPY Mn) | 6,006 | 5,662 | 8,001 | 17,018 | 23,037 |
Financing cash flow (JPY Mn) | 27,282 | -17,247 | -48,046 | -18,212 | -25,384 |
Returns & Leverage Ratios (%) and Financial Ratios (x)
| Ratio | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
ROE, avg equity (%) | 7.5 | 6.6 | 5.9 | 6.4 | 8.0 |
ROA, NI / avg assets (%) | 3.5 | 3.1 | 2.9 | 3.2 | 3.9 |
ROIC, analyst: OI × (1 − 30%) / (net assets + net debt) (%) | 5.3 | 4.5 | 4.2 | 5.3 | 5.4 |
Current ratio (x) | 1.67 | 1.85 | 1.79 | 2.08 | 1.91 |
Total debt / equity (x) | 0.48 | 0.48 | 0.42 | 0.43 | 0.44 |
Net debt / equity (x) | 0.32 | 0.37 | 0.27 | 0.27 | 0.34 |
Net debt / EBITDA (x) | 2.27 | 2.83 | 2.23 | 1.86 | 2.22 |
Interest coverage, OI / interest expense (x) | 30.0 | 10.4 | 8.2 | 10.5 | 13.4 |
Asset turnover, sales / avg assets (x) | 1.06 | 1.22 | 1.16 | 1.18 | 1.16 |
Days sales outstanding | 135.0 | 120.4 | 129.8 | 119.8 | 120.3 |
Days inventory outstanding | 89.7 | 81.8 | 73.4 | 78.6 | 82.6 |
Days payables outstanding | 84.9 | 67.7 | 77.6 | 71.6 | 74.3 |
Cash conversion cycle (days) | 139.8 | 134.5 | 125.6 | 126.8 | 128.6 |
Revenue by Region (%) and Revenue by Region
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Overseas sales ratio (%) | 67.3 | 70.1 | 70.1 | 70.4 | 69.8 |
Japan sales ratio, derived (%) | 32.7 | 29.9 | 29.9 | 29.6 | 30.2 |
Implied overseas sales, analyst calc. (JPY Mn) | 525,315 | 639,940 | 631,004 | 665,253 | 679,003 |
Implied Japan sales, analyst calc. (JPY Mn) | 255,242 | 272,956 | 269,145 | 279,708 | 293,780 |
Region gross profit (JPY Mn)
| Region gross profit (JPY Mn) | Q1FY2026 | Q1FY2027 |
|---|---|---|
Domestic (incl. inter-regional adjustments) | 20,900 | 25,500 |
Greater China | 6,700 | 9,000 |
ASEAN | 4,500 | 5,700 |
Americas | 8,200 | 9,400 |
Europe | 3,300 | 4,800 |
Other | 300 | 400 |
Overseas total | 23,300 | 29,500 |
Valuation Snapshot
| Metric | Value | Source |
|---|---|---|
Last close | ¥1,152 (29 Sep 2026) | Kabuyoho |
52-week high / low | ¥1,306 (5 Aug 2026) / ¥712.1 (22 Jul 2025) | Yahoo Finance JP; Kabuyoho |
Move from 52-week low | +61.8% | Analyst calculation |
1-year total return | Directionally strongly positive given the Jul 2025 low of ¥712 | — |
Pre-split all-time low reference | ¥177.3 split-adjusted (13 Mar 2009) | Matsui |
Valuation Multiples
| Multiple | Nagase | Basis |
|---|---|---|
P/E (trailing) | 14.6x | EPS ¥78.89 |
P/E (forward, guidance) | 13.6x | EPS ¥84.59 |
P/E (forward, consensus) | ~11.6x | Consensus NI ¥40.65bn / ~408m shares ≈ EPS ¥99.7 (analyst calc.) |
P/B | 1.10x | BPS ¥1,043.19 |
EV/EBITDA (trailing) | ~9.7x | EV ≈ ¥470bn mkt cap + ¥142.7bn net debt + ¥8.6bn minorities = ¥621bn; EBITDA ¥64.3bn |
EV/Sales | ~0.64x | — |
Dividend yield (forecast) | 2.3% | DPS ¥27 |
Peer Comparison
| Company | P/E | P/B | Dividend yield |
|---|---|---|---|
Nagase | 13.30x | 1.08x | 2.40% |
Macnica Holdings | 16.49x | 1.89x | 2.71% |
Iwatani | 10.35x | 1.08x | 2.30% |
Inabata | ~10.2x (¥3,920 / FY2026 EPS ¥384.84; analyst calc.) | — | ~3.6% on FY2027 DPS ¥143 |
Consensus Item Details
| Consensus item | FY2027E |
|---|---|
Net sales (JPY Mn) | 1,079,500 |
Operating income (JPY Mn) | 52,000 |
Ordinary income (JPY Mn) | 51,500 |
Net income (JPY Mn) | 40,650 |
Per-Share Data and Dividends & Capital Returns
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
DPS (JPY, post-split) | 13.5 | 17.5 | 20.0 | 22.5 | 25.0 |
Total dividends paid (JPY Mn) | 5,876 | 7,150 | 9,281 | 9,557 | 9,604 |
Share buybacks (JPY Mn) | 6,006 | 5,662 | 8,001 | 17,018 | 23,037 |
Authorisation by Period
| Period | Authorisation | Status |
|---|---|---|
FY2025 | ¥17.0bn executed (incl. ToSTNeT-3) | Complete |
8 Dec 2025 – 31 Jan 2026 | Up to 3.5m pre-split shares / ¥8.0bn | Complete within FY2026's ¥23.0bn (cash basis) |
5 Aug – 30 Sep 2026 | ¥3.0bn | — |
Cancellation | Treasury shares cancelled in FY2026; issued shares 459.6m → 439.6m post-split basis | Complete |
Credit Ratings
| Agency | Rating |
|---|---|
R&I | A+ (long-term), a-1 (short-term) |
Moody's / S&P / Fitch | No rating identified |
Capital Instruments
| Instrument | Amount (JPY Mn) | Maturity bucket |
|---|---|---|
Short-term loans | 20,175 | <1 year |
Commercial paper | 47,000 | <1 year |
Current portion of long-term loans | 15,000 | <1 year |
Bonds | 40,000 | — |
Long-term loans | 50,000 |
|
Lease liabilities (long-term) | 16,077 |
|
Analyst Conclusions
Guidance and consensus
Company FY2027: sales ¥1.0tn (+2.8%), operating income ¥45.0bn (+0.6%; −9% excluding actuarial gains), NI ¥34.5bn (+4.2%), EPS ¥84.59, DPS ¥27. Under review at H1.
Consensus FY2027: OI ¥52.0bn (+16%), NI ¥40.65bn (+23%).
Plan FY2029: OI >¥50bn; ROE ≥9%; EPS +30% over three years.
Q1 FY2027 delivered 38% of full-year OI, so an upward revision at H1 is plausible. That depends on the durability of Middle East-driven price levels, which management itself expects to reverse.
Bull case
-
AI-packaging leverage. Nagase ChemteX's Q1 FY2027 OI nearly doubled to ¥1.7bn at a 17% margin. If a-SMC scales beyond small-volume production, Electronics could re-rate the group mix toward specialty-materials multiples.
-
Prinova repair. FY2027 guidance implies Prinova OI after amortisation of ¥5.1bn (+22%). The Nutrition loss is narrowing, and Solutions is growing. Every 1pt of Prinova margin is about ¥2.4bn of OI at FY2027 sales.
-
Capital-return engine. A 100% total payout, ¥87.6bn of investment securities available to sell and a 30% EPS-growth commitment give a mechanical path to ROE of 9% or more, even with modest operating growth.
Bear case
-
Earnings-quality and peak-cycle risk. FY2027 underlying guidance is −9% excluding the actuarial gain. Q1 strength came from crisis-driven pricing and inventory, and the subsequent reversal could produce inventory losses on a ¥195bn inventory base.
-
China concentration. At 22.8% of sales, with semiconductor materials sold into China, export-control escalation could hit the highest-margin segment.
-
Structural ROIC ceiling. About 5% ROIC on a ~¥577bn capital base, a ~129-day cash conversion cycle and Prinova's low margin mean much of the plan's ROE delivery is financial engineering (buybacks) rather than economic-profit growth.
Catalysts and monitorables (next 12 months)
| Timing | Catalyst / monitorable |
|---|---|
| Early Nov 2026 | H1 FY2027 results and full-year forecast reassessment (Middle East effects; potential upgrade toward consensus) |
| Ongoing | Naphtha and resin price trajectory; inventory levels and working-capital release |
| Ongoing | a-SMC volume ramp; Nagase ChemteX capacity additions; Nagase Circrea integration |
| Ongoing | Prinova Nutrition break-even; logistics costs; US tariff policy on ingredients |
| Ongoing | Deployment of the ¥100bn growth envelope (semiconductor-materials M&A) |
| Ongoing | Further buyback authorisations and cross-shareholding sales |
| Feb 2027 | Q3 FY2027 results |
| May 2027 | FY2027 results; first-year progress on Walk the Talk 2028; FY2028 guidance |
| Ongoing | US–China export-control developments; USD/JPY and RMB/JPY |
Analyst verdict
Nagase has done what it promised under ACE 2.0, and that is not trivial for a 190-year-old Japanese trading house. Operating income rose from ¥30.6bn in FY2024 to a record ¥44.7bn in FY2026. ROE moved from 5.9% to 8.0%. Gross margin expanded despite flat volumes, and shareholders received more than 100% of earnings for two consecutive years. The portfolio is clearly being reshaped toward proprietary manufacturing:
-
Nagase ChemteX's AI-packaging epoxies and the new a-SMC encapsulant
-
Nagase Circrea's circular high-purity chemicals
-
Nagase Diagnostics
The four-for-one split, a fourth independent director and the three-segment simplification show a management team focused on market valuation.
The equity story nevertheless remains a "good capital allocator in a low-return business" story rather than a structural compounder. Group ROIC of roughly 5% barely clears any reasonable cost of capital. Prinova, the largest single asset (¥214bn of sales), still earns roughly 2% after amortisation. The FY2027 guidance, read correctly, implies underlying operating profit down about 9%, flattered by a pension actuarial gain. The exceptional Q1 FY2027 was driven partly by a geopolitical price shock that management itself expects to reverse.
At ¥1,152 the stock trades at about 13.6x guided and about 11.6x consensus FY2027 EPS, 1.1x book and about 9.7x trailing EV/EBITDA, with a 2.3% yield and a mechanical buyback bid. That valuation is fair for a specialty distributor and leaves modest upside if the consensus ¥52bn operating income proves right. The H1 update in November is the key test of whether Q1 was structural or windfall.
Our stance: constructive but selective. The risk/reward favours accumulation on post-results weakness rather than chasing strength. The thesis should be monitored against three markers:
-
a-SMC volume scaling
-
Prinova margin progress toward 4% or more
-
working-capital discipline as commodity prices normalise
Failure on Prinova would cap the re-rating regardless of buybacks.
SOURCES (principal)
-
Nagase & Co., Ltd., Consolidated Financial Statements for the Fiscal Year Ended March 31, 2026 (Kessan Tanshin), 7 May 2026 — finance-frontend-pc-dist.west.edge.storage-yahoo.jp/disclosure/20260507/20260507518029.pdf
-
Nagase & Co., Ltd., FY2026 First Quarter Financial Briefing, 4 Aug 2026 — finance-frontend-pc-dist.west.edge.storage-yahoo.jp/disclosure/20260804/20260804508227.pdf
-
Nagase & Co., Ltd., Notice of Revision of Full-Year Consolidated Earnings Forecast, 6 Nov 2025 — kabuyoho-sls-disclose.ifis.co.jp
-
Yuho FY2026 extracts (corporate history, affiliates): Kitaishihon — kitaishihon.com/company/8012/story
-
Yuho FY2026 extracts (segments, shareholders, board, remuneration): The-Shashi — the-shashi.com/tse/8012/
-
S&P Global Market Intelligence data via StockAnalysis (income statement, balance sheet, cash flow) — stockanalysis.com/quote/tyo/8012/
-
Kabuyoho / IFIS consensus and price data — kabuyoho.jp
-
Matsui Securities and Traders.co.jp price data — finance.matsui.co.jp; traders.co.jp
-
FilingReader summaries (H1 FY2026, FY2026 results, Walk the Talk 2028) — filingreader.com
-
Houlihan Lokey transaction note (SACHEM Asia, US$101m) — hl.com
-
SACHEM press release, 18 Mar 2025 — sacheminc.com
-
Nagase Diagnostics press release, 1 May 2025 — group.nagase.com
-
Prinova / Aplinova press release, 2 Apr 2025 — prezly CDN
-
Nagase press releases via Kyodo News PR Wire (NWI, 27 May 2025; Pune, 1 Dec 2025)
-
Envalith company overview and segments (summaries of Yuho/IR) — envalith.com/en/companies/8012
-
Nagase CEO message (Apr 2023); notice of change of President (25 Jan 2023); ACE 2.0 plan document (2021); KPI notice (May 2022) — nagase.com
-
j-lic.com (auditor, registered address)
-
Inabata & Co. FY2026 results via Matsui, Yahoo Finance JP, Logmi and Gyokai Digest
-
KnowESG (Sustainalytics), DitchCarbon, Rubber World (2022 carbon-neutral declaration), sustainabilityreports.com (Integrated Report 2025 summary)
-
GlobalData company profile (Dodai Group stake; Nippon Express partnership) — globaldata.com
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansExecutive Leadership
Board of Directors
| Name | Title | Tenure / background | Independent | AGM approval |
|---|---|---|---|---|
Kenji Asakura (朝倉研二) | Representative Director, Chairman (Board Chair) | Joined Nagase Apr 1978; President 2015–Mar 2023; Chairman from Apr 2023 | No | 95.10% |
Hiroyuki Ueshima (上島宏之) | Representative Director, President & CEO | Joined Nagase Apr 1988; director since Jun 2022 (development); President & CEO since Apr 2023. | No | 95.28% |
Hiroshi Nagase (長瀬洋) | Director, Senior Adviser | Joined Apr 1977; President 1999–2015; later Chairman; founding-family member | No | 98.61% |
Tamotsu Isobe (磯部保) | Director, Executive Officer | Joined Apr 1992 | No | 99.33% |
Yoshihisa Shimizu (清水義久) | Director, Executive Officer | Joined Apr 1987; formerly GM Corporate Management Dept. (2022) | No | 99.33% |
Ritsuko Nonomiya (野々宮律子) | Outside Director | Began career at Peat Marwick Main (now KPMG), Sep 1987 | Yes | 95.19% |
Noriaki Horikiri (堀切功章) | Outside Director | Joined Kikkoman Apr 1974; former Kikkoman President & CEO (per analyst knowledge) | Yes | 99.65% |
Toshiaki Mikoshiba (神子柴寿昭) | Outside Director | Joined Honda Apr 1980; President of Honda Motor Europe; President & CEO of Honda North America (from 2016); elected 2023 | Yes | 99.66% |
Eriko Sakurai (桜井恵理子) | Outside Director (new, Jun 2026) | — | Yes | 99.58% |
Executive Leadership Team
| Name | Role | Source |
|---|---|---|
Natsuki Imamura | Executive Officer, GM Corporate Management Dept. (IR contact) | Kessan Tanshin FY2026 |
Kazuhiro Hanba | Executive Officer, Head of Corporate Management Division (Nov 2025) | Forecast revision notice, 6 Nov 2025 |
Kentaro Nagase | Executive Officer (from Apr 2023; New Value Creation Office) | Company notice, Jan 2023 |
Directors' Remuneration
| Category | Headcount | Total (JPY Mn) | Fixed (JPY Mn) | Bonus (JPY Mn) | Stock (JPY Mn) |
|---|---|---|---|---|---|
Directors (excl. outside) | 7 | 450 | 201 | 168 | 20 |
Audit & Supervisory Board members | 3 | 50 | 50 | 0 | 0 |
of which outside officers | 3 | 44 | 44 | 0 | 0 |
Total | 10 | 500 | 251 | 168 | 20 |
Directors' Remuneration (Annual)
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Total officer remuneration (JPY Mn) | 446 | 548 | 282 | 490 | 500 |
Major Shareholders
| Rank | Holder | Stake (%) | Shares (pre-split, thousand) |
|---|---|---|---|
| 1 | The Master Trust Bank of Japan (trust a/c) | 11.71 | 12,027 |
| 2 | Custody Bank of Japan (trust a/c) | 6.24 | 6,406 |
| 3 | Nagase & Co. Employee/Business Partner Shareholding Association (長瀬産業自社株投資会) | 4.46 | 4,576 |
| 4 | Nippon Life Insurance | 3.50 | 3,589 |
| 5 | Reiko Nagase (founding family) | 3.03 | 3,115 |
| 6 | Shunzo Nagase (founding family) | 2.62 | 2,688 |
| 7 | Sumitomo Mitsui Trust Bank | 2.58 | 2,653 |
| 8 | State Street Bank and Trust Co. 505001 | 2.57 | 2,643 |
| 9 | Nomura Custody Nominees (omnibus) | 2.22 | 2,281 |
| 10 | Sumitomo Mitsui Banking Corp. | 2.13 | 2,188 |
Competitive Landscape
Competitors by Segment
| Segment | Direct competitors | Notes |
|---|---|---|
Chemicals / resins trading (Materials) | Inabata & Co. (8098); Chori (8014); CBC Co. (private); Sojitz Plastics / Sojitz; Toyota Tsusho (chemicals & electronics); Mitsubishi Corp. / Mitsui & Co. chemical units; Itochu Chemical Frontier; Okura Industrial trading peers | Inabata is the closest listed specialty-chemicals trading peer |
Global specialty chemical distribution | Brenntag (DE); IMCD (NL); Azelis (BE); DKSH (CH, Performance Materials) | Larger, more acquisitive; higher margins at IMCD and Azelis |
Semiconductor packaging materials (Nagase ChemteX) | Resonac (ex-Showa Denko Materials); Sumitomo Bakelite; Namics (private); Shin-Etsu Chemical (encapsulants); Henkel (adhesives/encapsulants) | Nagase ChemteX is a niche leader in liquid molding compounds |
High-purity chemicals / developer (Nagase Circrea) | Tokuyama; Tama Chemicals; SACHEM (outside Asia); Kanto Chemical | TMAH supply and recycling niche |
Electronics trading | Macnica Holdings; Ryoyo Ryosan; Inabata (information-electronics) | — |
Food & nutrition ingredients (Prinova) | Brenntag Nutrition; IMCD Food & Nutrition; Azelis F&N; Glanbia Nutritionals; dsm-firmenich premix; Univar Solutions (private) | Prinova competes on breadth and premix/contract-manufacturing capability |
Saccharides / bio-ingredients (Nagase Viita) | Cargill; Ingredion; Roquette; Hayashibara-legacy trehalose has few direct producers | Strong niche position in trehalose and pullulan |
Diagnostics enzymes / reagents | Toyobo; Kikkoman Biochemifa; Roche CustomBiotech | — |
Automotive materials (Mobility) | Toyota Tsusho; Inabata; Sojitz | — |
Peer Comparison FY2024
| Company | FY / period | Revenue | Revenue growth | Operating margin | Net margin | R&D intensity | Source / reliability |
|---|---|---|---|---|---|---|---|
Nagase & Co. | FY ended Mar 2026 | ¥972.8bn | +2.9% | 4.6% | 3.4% | — | Kessan Tanshin (primary) |
Inabata & Co. | FY ended Mar 2026 | ¥832.7bn | -0.6% | 3.1% | 2.5% | — | Inabata Kessan Tanshin via Matsui/Logmi (verified) |
Brenntag SE | FY2024 (Dec) | ~€16.2bn | ~-7% | ~7% (operating EBITA) | — | n/m | — |
IMCD N.V. | FY2024 (Dec) | ~€4.7bn | ~+6% | ~11% (operating EBITA) | — | n/m | — |
“—” = not publicly disclosed.
Competitor Detail
| Inabata & Co. metric | FY2024 | FY2025 | FY2026 |
|---|---|---|---|
Net sales (JPY Mn) | 766,022 | 837,838 | 832,745 |
Operating income (JPY Mn) | 21,190 | 25,824 | 26,164 |
Net income (JPY Mn) | 20,000 | 19,833 | 20,632 |
Recent Developments
--



